EP4144761A4 - Rekombinantes protein mit fusioniertem interferon-beta-mutein und -antikörper sowie pharmazeutische zusammensetzung damit - Google Patents

Rekombinantes protein mit fusioniertem interferon-beta-mutein und -antikörper sowie pharmazeutische zusammensetzung damit Download PDF

Info

Publication number: EP4144761A4
Authority: EP; European Patent Office
Prior art keywords: fusioned; interferon; antibody; pharmaceutical composition; recombinant protein
Prior art date: 2020-04-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21797179.5A

Other languages

English (en)

French (fr)

Other versions

EP4144761A1 (de

Inventor

Hae Min Jeong

Chan Gyu Lee

Ji Sun Lee

Jun Young Choi

Na Young Kim

Yong Jin Lee

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abion Inc

Genopharm Inc

Original Assignee

Abion Inc

Genopharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-04-29

Filing date

2021-04-28

Publication date

2024-05-29

2021-04-28 Application filed by Abion Inc, Genopharm Inc filed Critical Abion Inc

2023-03-08 Publication of EP4144761A1 publication Critical patent/EP4144761A1/de

2024-05-29 Publication of EP4144761A4 publication Critical patent/EP4144761A4/de

Status Pending legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Mycology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP21797179.5A 2020-04-29 2021-04-28 Rekombinantes protein mit fusioniertem interferon-beta-mutein und -antikörper sowie pharmazeutische zusammensetzung damit Pending EP4144761A4 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20200052911		2020-04-29
PCT/KR2021/005407 WO2021221470A1 (ko)	2020-04-29	2021-04-28	인터페론-베타 변이체와 항체가 융합된 재조합 단백질 및 이를 포함하는 약학 조성물

Publications (2)

Publication Number	Publication Date
EP4144761A1 EP4144761A1 (de)	2023-03-08
EP4144761A4 true EP4144761A4 (de)	2024-05-29

Family

ID=78373731

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21797179.5A Pending EP4144761A4 (de)	2020-04-29	2021-04-28	Rekombinantes protein mit fusioniertem interferon-beta-mutein und -antikörper sowie pharmazeutische zusammensetzung damit

Country Status (6)

Country	Link
US (1)	US20240270807A1 (de)
EP (1)	EP4144761A4 (de)
JP (1)	JP7610816B2 (de)
KR (1)	KR102651002B1 (de)
CN (1)	CN116075523A (de)
WO (1)	WO2021221470A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20210021861A (ko) *	2019-08-19	2021-03-02	(주)제노팜	사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
US20230159605A1 (en) *	2020-04-29	2023-05-25	Abion Inc.	Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
AU2024389329A1 (en) *	2023-11-28	2026-07-09	Abion Inc.	Novel use of interferon epsilon

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0218825A1 (de) *	1982-10-19	1987-04-22	Cetus Corporation	Cystein-verminderte Muteine von Interferon-beta, ihre Herstellung, Zusammensetzungen, die diese Muteine enthalten sowie Strukturgene, Vektoren und Organismen geeignet zur Verwendung bei der Herstellung der genannten Muteine und deren Herstellung
WO2004020468A2 (en) *	2002-08-28	2004-03-11	Maxygen Aps	Interferon beta-like molecules for treatment of cancer
EP3266801A1 (de) *	2015-03-03	2018-01-10	Abion Inc.	An eine variante von humanem interferon-beta konjugiertes immunocytokin und verfahren zur herstellung davon
US20190194284A1 (en) *	2016-05-13	2019-06-27	Orionis Biosciences Nv	Targeted mutant interferon-beta and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL90047A (en) *	1982-10-19	1992-12-01	Cetus Oncology Corp	Cysteine-depleted biologically active muteins other than interferon - '
US4588585A (en) *	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
AU766190B2 (en) *	1998-10-16	2003-10-09	Biogen Idec Ma Inc.	Interferon-beta fusion proteins and uses
US7670595B2 (en) *	2004-06-28	2010-03-02	Merck Patent Gmbh	Fc-interferon-beta fusion proteins
KR100781666B1 (ko) *	2004-11-02	2007-12-03	신영기	인간 인터페론-베타 변이체
US20080038224A1 (en) *	2006-03-28	2008-02-14	Thierry Guyon	Modified interferon-beta (IFN-beta) polypeptides
WO2016163764A2 (ko) *	2015-04-07	2016-10-13	에이비온 주식회사	인터페론 베타 변이체의 안정화 제제
KR20180025743A (ko) *	2016-09-01	2018-03-09	에이비온 주식회사	인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
WO2020091811A1 (en)	2018-11-02	2020-05-07	Google Llc	Systems and methods for providing multi-part persistent content

2021
- 2021-04-28 WO PCT/KR2021/005407 patent/WO2021221470A1/ko not_active Ceased
- 2021-04-28 CN CN202180046271.9A patent/CN116075523A/zh active Pending
- 2021-04-28 EP EP21797179.5A patent/EP4144761A4/de active Pending
- 2021-04-28 US US17/922,179 patent/US20240270807A1/en active Pending
- 2021-04-28 JP JP2022566371A patent/JP7610816B2/ja active Active
- 2021-04-29 KR KR1020210056025A patent/KR102651002B1/ko active Active

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0218825A1 (de) *	1982-10-19	1987-04-22	Cetus Corporation	Cystein-verminderte Muteine von Interferon-beta, ihre Herstellung, Zusammensetzungen, die diese Muteine enthalten sowie Strukturgene, Vektoren und Organismen geeignet zur Verwendung bei der Herstellung der genannten Muteine und deren Herstellung
WO2004020468A2 (en) *	2002-08-28	2004-03-11	Maxygen Aps	Interferon beta-like molecules for treatment of cancer
EP3266801A1 (de) *	2015-03-03	2018-01-10	Abion Inc.	An eine variante von humanem interferon-beta konjugiertes immunocytokin und verfahren zur herstellung davon
US20190194284A1 (en) *	2016-05-13	2019-06-27	Orionis Biosciences Nv	Targeted mutant interferon-beta and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KYOUNG SONG ET AL: "Glycoengineering of Interferon-[beta] 1a Improves Its Biophysical and Pharmacokinetic Properties", PLOS ONE, vol. 9, no. 5, 23 May 2014 (2014-05-23), pages e96967, XP055496990, DOI: 10.1371/journal.pone.0096967 *
LEE CHAN GYU ET AL: "Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing", vol. 11, 8 January 2021 (2021-01-08), pages 608774, XP055862548, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832035/pdf/fphar-11-608774.pdf> DOI: 10.3389/fphar.2020.608774 *
See also references of WO2021221470A1 *

Also Published As

Publication number	Publication date
JP2023528582A (ja)	2023-07-05
CN116075523A (zh)	2023-05-05
WO2021221470A1 (ko)	2021-11-04
JP7610816B2 (ja)	2025-01-09
KR102651002B1 (ko)	2024-03-25
EP4144761A1 (de)	2023-03-08
US20240270807A1 (en)	2024-08-15
KR20210133897A (ko)	2021-11-08

Legal Events

Date	Code	Title	Description
2021-11-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-02-03	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-02-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-03-08	17P	Request for examination filed	Effective date: 20221129
2023-03-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-08-02	DAV	Request for validation of the european patent (deleted)
2023-08-02	DAX	Request for extension of the european patent (deleted)
2024-05-29	A4	Supplementary search report drawn up and despatched	Effective date: 20240426
2024-05-29	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20240422BHEP Ipc: A61P 35/00 20060101ALI20240422BHEP Ipc: C12N 15/85 20060101ALI20240422BHEP Ipc: C12N 15/62 20060101ALI20240422BHEP Ipc: C07K 14/52 20060101ALI20240422BHEP Ipc: C07K 16/32 20060101AFI20240422BHEP
2025-12-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2026-01-21	17Q	First examination report despatched	Effective date: 20251218

Publication	Publication Date	Title
EP4361163A4 (de)	2025-07-16	Proteininhibitor oder abbaumittel, pharmazeutische zusammensetzung damit und pharmazeutische verwendung
EP4257604A4 (de)	2024-11-13	Pharmazeutische zusammensetzung mit anti-tslp-antikörper und verwendung davon
ATE471946T1 (de)	2010-07-15	Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
BRPI0507118A (pt)	2007-06-19	polipeptìdeos de interferon humano modificado e seus usos
EP4389771A4 (de)	2026-02-25	Fusionsprotein mit anti-tigit-antikörper und tgf-beta-r sowie pharmazeutische zusammensetzung und verwendung davon
ECSP088909A (es)	2008-12-30	ANTICUERPOS BLOQUEANTES DE LA FUNCIÓN DE LA INTEGRINA 5ß1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA
EP4215547A4 (de)	2024-12-04	Gegen 4-1bb gerichteter einzeldomänenantikörper, fusionsprotein davon, pharmazeutische zusammensetzung und verwendung davon
EP4317179C0 (de)	2025-10-29	Gip- und glp-1-doppelrezeptoragonist, pharmazeutische zusammensetzung und verwendung
EP4104858A4 (de)	2023-11-29	Pharmazeutische zusammensetzung mit anti-il-4r-antikörper und verwendung davon
EP4376809A4 (de)	2025-06-04	Pharmazeutische anti-pd-1-antikörperzusammensetzung und verwendung davon
EP4582455A4 (de)	2026-03-25	Fusionsprotein mit taci-polypeptid und verwendung davon
EP4433497A4 (de)	2026-02-25	D-domäne enthaltende polypeptide und deren verwendungen
EP4314073A4 (de)	2025-02-19	Upar-antikörper und fusionsproteine damit
EP4400505A4 (de)	2025-08-27	Peptid-harnstoff-derivat, pharmazeutische zusammensetzung damit und anwendung davon
EP4293045A4 (de)	2024-12-11	Pharmazeutische anti-tigit-antikörperzusammensetzung und anwendung davon
EP4416182A4 (de)	2025-09-17	Anti-cd3-antikörper mit kreuzreaktivität gegen menschliche und cynomolgus-proteine
EP4190353A4 (de)	2024-02-14	Pharmazeutische anti-pd-1-antikörperzusammensetzung und verwendung davon
EP4501943A4 (de)	2025-08-27	Peptid mit antidiabetischer wirkung, peptidkomplex und verwendung davon
EP4410841A4 (de)	2025-08-13	Anti-il23-antikörperfusionsprotein und verwendungen davon
KR102192192B9 (ko)	2021-08-23	보툴리눔 독소 및 세포 투과성 펩타이드를 포함하는 재조합 단백질과 이를 포함하는 화장료 조성물
EP4524151A4 (de)	2026-05-06	Interleukin21-variante und fusionsprotein damit und verwendungen davon
EP4563591A4 (de)	2026-04-15	Rekombinantes fusionsprotein zur antigenverabreichung und verwendungen davon
EP4171611A4 (de)	2024-10-02	Interleukin-22-fusionsproteine sowie pharmazeutische zusammensetzungen daraus und therapeutische anwendungen davon
EP4376870A4 (de)	2025-07-23	Interleukin-2-muteine, fusionsproteine, pharmazeutische zusammensetzungen und therapeutische anwendungen
EP4286376A4 (de)	2025-06-11	Pyrimidinderivat mit proteinkinasehemmender wirkung und pharmazeutische therapeutische zusammensetzung damit